STEP II: SGPT (ALT) and SGOT (AST) < 2.5 times the upper limit of normal (within 28 days prior to randomization to Step II)Xx_NEWLINE_xXSerum bilirubin =< institutional upper limit of normal (IULN) within 28 days prior to sub-study registration; for patients with liver metastases, bilirubin must be =< 5 x IULNXx_NEWLINE_xXSTEP 3 CROSSOVER REGISTRATION (OPTIONAL): AST and ALT both =< 5 x institutional upper limit of normal (IULN) within 14 days prior to step 3 crossover registrationXx_NEWLINE_xXAST/ALT =< 3 x upper limit of normal (ULN)Xx_NEWLINE_xXPatients must have AST and ALT =< 2.5 x institutional upper limit of normal (IULN)Xx_NEWLINE_xXTotal bilirubin =< 1.5 x institutional upper limit of normal (IULN) (=< 5 x IULN if secondary to lymphoma, Gilbert’s syndrome, or medication related [e.g., indinavir, tenofovir, atazanavir]) within 28 days prior to registrationXx_NEWLINE_xXDirect bilirubin =< 3 x upper limit of normal (ULN), unless suspected leukemic involvement of the liverXx_NEWLINE_xXAST =< 8 x upper limit of normal (ULN)Xx_NEWLINE_xXAST and ALT =< 3.0 x institutional upper limit of normal (IULN) within 14 days prior to registrationXx_NEWLINE_xXRegistration Step 3 – Maintenance: Patients must have AST and ALT =< 3.0 x institutional upper limit of normal (IULN) within 14 days prior to registrationXx_NEWLINE_xXALT (SGPT) < 10 x upper limit of normal (ULN) for ageXx_NEWLINE_xXAlanine transaminase (ALT) < 3.0x the upper limit of normal (ULN)Xx_NEWLINE_xXLiver function tests (including ALT, AST, and total bilirubin), outside of the range of local laboratory normal at ScreeningXx_NEWLINE_xXCreatine Kinase ? 1.5x the upper limit of normalXx_NEWLINE_xXAspartate amino transferase (AST) or alanine amino transferase (ALT) > 2.5 times the upper limit of normal (ULN).Xx_NEWLINE_xXALT (SGPT) < 10 x upper limit of normal (ULN) for ageXx_NEWLINE_xXPatients with Gilbert's syndrome are eligible provided the total bilirubin is =< 3 and the remainder of the liver function tests (ALT, AST, alkaline phosphatase [ALK Phos]) are within the institutional normal rangeXx_NEWLINE_xXSerum bilirubin less than two times the institutional upper limits of normal (ULN); higher levels are acceptable if these can be attributed to active hemolysis, ineffective erythropoiesis, or Gilbert’s diseaseXx_NEWLINE_xXPlatelets >= 100 x 10^3/mm^3 (or >= lower limit of institutional normal value)Xx_NEWLINE_xXELIGIBILITY CRITERIA - PHASE II (ARM D): Adequate liver function with AST/ALT less than 3 X upper limit of normal and total bilirubin less than 2 mg/dL within 7 days prior to first dose of study agentXx_NEWLINE_xXObtained =< 21 days prior to registration: Alanine amino transferase (ALT) < 2.5 X ULN, with normal bilirubin; NOTE: Concomitant elevations in bilirubin and ALT above 1.5 x ULN (upper limit of normal) is not permittedXx_NEWLINE_xXLiver function abnormalities as indicated by ongoing hepatic enzyme elevation (AST or ALT) >2 times upper limit of normal (ULN)Xx_NEWLINE_xXINCLUSION CRITERIA FOR SECOND-LINE THERAPY: Bilirubin =< 1.5 X the upper limit of normalXx_NEWLINE_xXINCLUSION CRITERIA FOR SECOND-LINE THERAPY: For patients with known hepatic metastases, AST and ALT =< 5 X the upper normal limit of institution's normal rangeXx_NEWLINE_xXINCLUSION CRITERIA FOR THIRD-LINE THERAPY: AST and ALT =< 3 X the upper normal limit of institution's normal rangeXx_NEWLINE_xXINCLUSION CRITERIA FOR THIRD-LINE THERAPY: Bilirubin =< 1.5 X the upper limit of normalXx_NEWLINE_xXINCLUSION CRITERIA FOR THIRD-LINE THERAPY: For patients with known hepatic metastases, AST and ALT =< 5 X the upper normal limit of institution's normal rangeXx_NEWLINE_xXAlkaline phosphatase < 2.5 x upper limit of normal if no documented liver disease or < 6 x upper limit of normal if documented liver or bone diseaseXx_NEWLINE_xXSerum conjugated (direct) bilirubin < 2x upper limit of normal for age as per local laboratory. Patients with hyperbilirubinemia as a consequence of hyperhemolysis, or who experience a sudden, profound change in the serum hemoglobin after a RBC transfusion are not excluded.Xx_NEWLINE_xXSerum glutamate pyruvate transaminase (SGPT) =< 10 x the institutional upper limit of normal for patients on Stratum A; Stratum B patients must have SGPT =< 4 x the institutional upper limit of normal.Xx_NEWLINE_xXTotal bilirubin =< 1.5 x upper limit of normal (ULN); NOTE: exceptions can be granted from principal investigator (PI) for instances of Gilbert’s disease, and/or primarily indirect bilirubinemia, if due to recent transfusion and/or hemolysisXx_NEWLINE_xXSerum amylase =< 1.5 x institutional upper limit of normalXx_NEWLINE_xXSerum bilirubin ? 1.5 x upper normal limit (UNL) except patients with Gilbert's syndromeXx_NEWLINE_xXBlood urea nitrogen (BUN) =< 1.5 x upper limit of normal rangeXx_NEWLINE_xXPIK3CA WILD TYPE COHORT (closed 03/17/2016): AST(SGOT)/ and ALT(SGPT) =< 2.5 X institutional upper limit normalXx_NEWLINE_xXENDOCRINE RESISTANT AND ADJUVANT COHORT: AST(SGOT)/ and ALT(SGPT) =< 2.5 X institutional upper limit normalXx_NEWLINE_xXCreatinine less than or equal to 1.5 x institutional upper limit of normal (ULN), equivalent to the active version of the NCI adverse event (AE) grade 1Xx_NEWLINE_xXSGPT (ALT) =< 5 x upper limit of normal (ULN) for ageXx_NEWLINE_xXIf requires pheresis to collect blood, creatinine (Cre) < 1.5 upper limit of normalXx_NEWLINE_xXIf requires pheresis to collect blood, aspartate aminotransferase (AST) < 1.5 upper limit of normalXx_NEWLINE_xXIf requires pheresis to collect blood, prothrombin time (PT) < 1.5 upper limit normalXx_NEWLINE_xXIf requires pheresis to collect blood, partial thromboplastin time (kaolin) (PTTK) < 1.5 upper limit normalXx_NEWLINE_xXAST less than 5 times the upper limit of normalXx_NEWLINE_xXBilirubin < 1.5 mg/dL, ALT < 3 x upper limit of normalXx_NEWLINE_xXPlatelets >= institutional lower limitXx_NEWLINE_xXEvidence of significant renal, hepatic, hematologic, or immunologic disease determined by any one of the following: Estimated creatinine clearance <30 mL/min; ALT or AST level greater than 10-fold the upper limit of normal or total bilirubin greater than 3-fold the upper limit of normal; Manifestations of end-stage liver disease, such as ascites or hepatic encephalopathy; Thrombocytopenia; or CD4+ T cell count below 200 cells per ?LXx_NEWLINE_xXMeasurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of > 2 times the upper limit of normal of each institution is requiredXx_NEWLINE_xXMeasurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of > 2 times the upper limit of normal of each institution is requiredXx_NEWLINE_xXFor WM, serum immunoglobulin M (IgM) with a minimum IgM level of ? 2 times the upper limit of normal (ULN).Xx_NEWLINE_xXThere is no upper age limit but the patients must be able to medically tolerate the regimenXx_NEWLINE_xXINCLUSION - PROCUREMENT: If pheresis required to collect blood:\r\n* Creatinine <1.5 × upper limit normalXx_NEWLINE_xXINCLUSION - PROCUREMENT: If pheresis required to collect blood:\r\n* Aspartate aminotransferase (AST) < 1.5 × upper limit normalXx_NEWLINE_xXINCLUSION - TREATMENT: AST less than 5 times the upper limit of normalXx_NEWLINE_xXLiver function: total bilirubin < 2x the upper limit of normal and alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5x the upper normal limit (Patients with Gilbert's Disease are permitted to exceed the defined bilirubin value of 2x the upper limit of normal, however measurements of direct bilirubin should be done to confirm this diagnosis).Xx_NEWLINE_xXINCLUSION - INFUSION: Patients with bilirubin ? 3 x upper limit of normalXx_NEWLINE_xXObtained =< 21 days prior to registration and confirmed prior to the first dose of study drug: Alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal (ULN)Xx_NEWLINE_xXFasting triglycerides =< 1.5 x upper limit of normal (ULN)Xx_NEWLINE_xXTotal bilirubin =< 2 x institutional upper limit of normal (IULN) except for Gilbert’s disease or when in the opinion of treating physician elevated levels are due to direct involvement of leukemia (e.g., hepatic infiltration or biliary obstruction due to leukemia)Xx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (ULN); this will not apply to subjects with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with the study sponsorXx_NEWLINE_xXAST and ALT ? upper limit of normalXx_NEWLINE_xXMg ? lower limit of normalXx_NEWLINE_xXThyrotropin/25-hydroxyvitamin D levels < lower limit of normalXx_NEWLINE_xXBilirubin ? 2X upper limit of normalXx_NEWLINE_xXAspartate transaminase (AST) ? 3X upper limit of normalXx_NEWLINE_xXHepatic: direct bilirubin ? 3 x upper limit of normal, or AST/ALT ? 5 x upper limit of normalXx_NEWLINE_xXTotal bili ? 1.5 x upper limit or normalXx_NEWLINE_xXAlanine transaminase (ALT) and aspartate transaminase (AST) within 1.5x upper limit of normal;Xx_NEWLINE_xXINCLUSION CRITERIA FOR STRATUM C: ALT (SGPT) =< 3 x institutional upper limit of normalXx_NEWLINE_xXPlatelets >= institutional lower limit of normalXx_NEWLINE_xXELIGIBILITY CRITERIA AT TIME OF TREATMENT: Patients with bilirubin ? 3 x upper limit of normalXx_NEWLINE_xXPatients with bilirubin ? 2x upper limit of normalXx_NEWLINE_xXPartial thromboplastin time =< 1.66 times upper limit of normalXx_NEWLINE_xXKnown uncompensated hypothyroidism (defined as greater than 2x upper limit of normal not treated with replacement hormone)Xx_NEWLINE_xXSerum alanine transaminase (ALT) and/or aspartate transaminase (AST) values < 3 x the upper limit of normal (ULN) of the local laboratory reference rangeXx_NEWLINE_xXAST/SGOT and ALT/SGPT < 2.5 x the institutional upper limit of normal (IULN).Xx_NEWLINE_xXPART II: SGOT and SGPT =< 3 x upper limit of normal (ULN)Xx_NEWLINE_xXHave adequate organ function, including: Absolute neutrophil count (ANC) at least 1.5 x 109/Liter (L), platelets at least 100 x 109/L, and hemoglobin at least 8 grams/deciliter (g/dL); bilirubin no more than 1.5 times upper limits of normal; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) no more than 2.0 times upper limits of normal; Serum creatinine no more than 1.5 times upper limits of normal or calculated creatinine clearance >45 milliliters/minute (mL/min)Xx_NEWLINE_xXAST ? 5 x upper limit of normalXx_NEWLINE_xXTotal bilirubin =< 1.5 x institutional upper limit of normal, unless related to leukemic infiltration or hemolysisXx_NEWLINE_xXTotal bilirubin < 1.5 x upper limit of reference range (< 3 x upper limit of reference range in patients with Gilbert's disease)Xx_NEWLINE_xXAlkaline phosphatase =< 2.5 x upper limit of reference range (or =< 5 x upper limit of reference range if considered to be related to liver or bone metastases by the principal investigator [PI])Xx_NEWLINE_xXSubjects must have serum lactate dehydrogenase (LDH) > institutional upper limit of normal (ULN) at time of study enrollmentXx_NEWLINE_xXShould be performed within 10 days of treatment initiation: serum bilirubin ? 1.5 x institutional upper limit of normal (ULN); this will not apply to subjects with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physicianXx_NEWLINE_xXDirect bilirubin =< 2 x upper limit of normal (ULN) unless deemed to be related to underlying leukemia.Xx_NEWLINE_xXBaseline serum troponin above the upper limit of normalXx_NEWLINE_xXBaseline serum B-type natriuretic peptide (BNP) above the age-adjusted upper limit of normalXx_NEWLINE_xXBaseline amylase above the upper limit of normalXx_NEWLINE_xXDirect bilirubin ? 2 X institutional upper limit of normal (ULN) (unless due to known Gilbert’s syndrome or compensated hemolysis directly attributable to CLL)Xx_NEWLINE_xXPatients with 5-­hydroxyindoleacetic acid (HIAA) levels above or below the upper limit of normal range (normal: 0 to 15 mg/24 hours) and those with unknown values at baseline are allowed to participateXx_NEWLINE_xXSeverely impaired renal or hepatic function (eg, serum creatinine level > 2 mg/dL [176.8 ?mol/L], blood urea nitrogen level >50 mg/dL [17.9 mmol/L], serum aspartate aminotransferase [AST] level >3 times the upper limit of normal [ULN], or serum alanine aminotransferase [ALT] level > 3 times ULN).Xx_NEWLINE_xXPatients with uncorrectable electrolyte abnormalities with potassium (K) > ULN (upper limit of normal)Xx_NEWLINE_xXCoagulopathy or receiving anticoagulants that result in PT or aPTT values greater than 1.3 X upper limit of normal or elevated D-dimer of decreased fibrinogenXx_NEWLINE_xXResearch participant serum total bilirubin or transaminases does not exceed 2 x normal limitXx_NEWLINE_xXAST (SGOT)/ALT(SGPT) (only if elevated liver function tests [LFTs] are due to disease) =< 5.0 x institutional upper limit of normalXx_NEWLINE_xXBilirubin level above the normal reference rangeXx_NEWLINE_xXCorrected calcium value =< 1.1 x upper limit of normal (ULN)Xx_NEWLINE_xXPT-INR > 2x upper limit of normal reference range (ULN) in the absence of anticoagulation within 7 days prior to Day 1Xx_NEWLINE_xXGamma-glutamyl transpeptidase (GGT) must be =< 2.5 x institutional upper limit of normal (grade 1 or less per CTCAE 4)Xx_NEWLINE_xXRenal and hepatic disorders with values of >1.5 times the upper limit of normal (ULN) or blood disorders (upon clinician judgment);Xx_NEWLINE_xXAspartic transaminase (AST) =< 1.5 x upper limit of normal (ULN).Xx_NEWLINE_xXAST and ALT ? 5 x the upper limit of normalXx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (ULN); this will not apply to subjects with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physicianXx_NEWLINE_xXQuantitative serum IgG levels for subjects with IgG MM must not exceed the institutional upper limit of normal (ULN)Xx_NEWLINE_xXCardiac troponin value above the Upper Limit of Normal (ULN);Xx_NEWLINE_xXSerum lactate dehydrogenase (LDH) level =< 1.5 upper limit of normal (ULN) within 28 days prior to enrollmentXx_NEWLINE_xXAST and ALT ? 3.0 X the upper normal limit of institution's normal rangeXx_NEWLINE_xXPT and PTT must be ? 1.5 X upper normal limit of institution's normal rangeXx_NEWLINE_xXPhosphorus =< institutional upper limit of normalXx_NEWLINE_xXClinically significant kidney (e.g. glomerular filtration rate [GFR] =< 45ml/minute or creatinine of >= 2 mg/dl) or liver dysfunction (e.g. aspartate aminotransferase [AST]/alanine aminotransferase (ALT) and/or bilirubin >= 2 times upper limit of normal [ULN]) at the time of enrollment that may prevent from safely using chemotherapy; such patients may be allowed to receive low-intensity chemotherapy; patients with elevated bilirubin secondary to Gilbert syndrome will not be excluded; discussion with the principal investigator is encouraged if further clarification is requiredXx_NEWLINE_xXREP ELIGIBILITY: Serum ALT and AST less than three times the institutional upper limit of normalXx_NEWLINE_xXCHEMOTHERAPY/CELL INFUSION ELIGIBILITY: Serum ALT and AST less than three times the institutional upper limit of normalXx_NEWLINE_xXCHEMOTHERAPY/CELL INFUSION ELIGIBILITY: PT and PTT less than or equal to 1.5 times the institutional upper limit of normalXx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (ULN); (this will not apply to subjects with confirmed Gilbert's syndrome [persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology], who will be allowed only in consultation with their physician)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x the upper normal limit of institution's normal range, at the time of enrollment; for subjects with liver metastases, AST and ALT =< 5 x the upper normal limit of institution's normal range are acceptable as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophiliaXx_NEWLINE_xXTotal bilirubin =< 1.5 x the upper normal limit of institution's normal range, at the time of enrollment; for subjects with liver metastases, total bilirubin > 1.5 - 3.0 x the upper normal limit of institution's normal range are acceptable as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophiliaXx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (ULN). This will not apply to subjects with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.Xx_NEWLINE_xXSTUDY TREATMENT: Serum aminotransferase value less than 1.5 times the upper limit of the normal rangeXx_NEWLINE_xXMust have had an elevated serum CA125 level twice the upper limit of normal (per reference lab normal range) measured within 4 weeks of enrollment.Xx_NEWLINE_xXHepatic dysfunction defined as a bilirubin >1.5 times the upper normal limits, LDH, SGOT and SGPT>2 times upper limits of normal or albumin <3.5 g/dL.Xx_NEWLINE_xXBilirubin < 1.5 x upper limit of normal (ULN) unless believed due to leukemic infiltrationXx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (ULN); this will not apply to subjects with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physicianXx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (ULN). This will not apply to subjects with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physicianXx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (ULN). This will not apply to subjects with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only upon treating physician, principal investigators (PI) or co-PIs approvalXx_NEWLINE_xXProthrombin time (PT) within 2 seconds of the upper limit of normal (institutional normal ratio [INR] =< 1.8)Xx_NEWLINE_xXSerum bilirubin =< 1.5 x upper normal limit (UNL), except patients with Gilbert's syndromeXx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (ULN). (This will not apply to subjects with confirmed Gilbert’s syndrome [persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology], who will be allowed only in consultation with their physician)Xx_NEWLINE_xXLiver aminotransferase levels greater than 3 times the laboratory's upper limit of normal (greater than 5 times the laboratory's upper limit of normal if the liver is known to be involved with tumor)Xx_NEWLINE_xXHemoglobin within 10% of upper and lower limit of normal range of test (gender based)Xx_NEWLINE_xXPlatelet within 10% of upper and lower limit of normal range of testXx_NEWLINE_xXALT < 2 x upper limit of normalXx_NEWLINE_xXPRE-SCREENING: Must have normal organ function with liver function tests (LFTs) < 2.5 x upper limit of normal (ULN)Xx_NEWLINE_xXDONOR: Hemoglobin within 10% of upper and lower limit of normal range of test (gender based for hemoglobin)Xx_NEWLINE_xXDONOR: WBC within 10% of upper and lower limit of normal range of test (gender based for hemoglobin)Xx_NEWLINE_xXDONOR: Platelet within 10% of upper and lower limit of normal range of test (gender based for hemoglobin)Xx_NEWLINE_xXDONOR: ALT < 2 x upper limit of normalXx_NEWLINE_xXTotal bilirubin: =< 1.5 institutional upper limit of normal (ULN); if potential due to lymphoma, the first cycle may be given without ibrutinib and if transaminitis and bilirubinemia improves to meet parameters, participant mat be enrolled on the clinical trialXx_NEWLINE_xXSerum lactate dehydrogenase (LDH) not greater than 1.5 times the upper limit of the local laboratory assay within 14 days of RPLNDXx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (ULN) within 28 days prior to study registration; this will not apply to subjects with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physicianXx_NEWLINE_xXCELL PROCUREMENT: Bilirubin =< 1.5 x upper limit of normal (ULN), unless attributed to Gilbert’s syndrome, obtained within 72 hrs prior to procurementXx_NEWLINE_xXLYMPHODEPLETION: Bilirubin =< 1.5 x upper limit of normal (ULN) unless attributed to Gilbert’s syndrome, obtained within 72 hrs prior to procurementXx_NEWLINE_xXTo be performed within 10 business days prior to day 1: Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) unless demonstrated Hodgkin lymphoma involvement of the liverXx_NEWLINE_xXDirect bilirubin =< 2 X institutional upper limit of normal (ULN) (unless due to known Gilbert’s syndrome or compensated hemolysis directly attributable to CLL)Xx_NEWLINE_xXCreatinine =< 1.2 x normal range prior to biopsyXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x the upper normal limit of institution's normal range; for subjects with liver metastases, AST and ALT < 5 x the upper normal limit of institution's normal range are acceptable as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophiliaXx_NEWLINE_xXTotal bilirubin =< 1.5 x the upper normal limit of institution's normal range; for subjects with liver metastases, total bilirubin > 1.5 - 3.0 x the upper normal limit of institution's normal range are acceptable as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophiliaXx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (ULN); this will not apply to subjects with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physicianXx_NEWLINE_xXBilirubin =< 2.5 x institutional upper limit of normal (IULN) unless elevation is thought to be due to hepatic infiltration by AML, Gilbert’s syndrome, or hemolysis (assessed within 14 days prior to registration)Xx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (ULN); this will not apply to subjects with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physicianXx_NEWLINE_xXPHASE II: AST (SGOT) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXPHASE II: ALT (SGPT) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXAlkaline phosphatase < 2.5 x upper limit of normal, unless bone metastasis is present (< 5 x upper limit of normal) in the absence of liver metastasisXx_NEWLINE_xXHave AST, ALT, GGT, and AP that are ?2.5*upper limit of normal (ULN) and normal bilirubin (total and direct) regardless of liver involvement.Xx_NEWLINE_xXPHASE II SCLC: AST (SGOT)/ALT (SGPT) =< 2.5 X institutional upper limit of normal (=< 5X ULN if liver mets)Xx_NEWLINE_xXUROTHELIAL CARCINOMA EXPANSION COHORT: AST(SGOT)/ALT(SGPT) =< 2.5 X institutional upper limit of normal (=< 5X ULN if liver mets)Xx_NEWLINE_xXmCRPC EXPANSION COHORT: AST(SGOT)/ALT(SGPT) =< 3 X institutional upper limit of normal (=< 5X ULN if liver mets)Xx_NEWLINE_xXDirect bilirubin or ALT > 2 x upper limit of normal, unless these abnormalities are thought to be related to Gilbert’s disease or leukemic infiltration of hepatic parenchymaXx_NEWLINE_xXAdequate organ function =< 21 days prior to registration:\r\n* Aspartate transaminase (AST) level =< 2.5 x upper limit of normal (ULN) and alanine transaminase (ALT) =< 3 x upper limit of normal (ULN)\r\n* Total bilirubin level of =< 1.5 x ULN\r\n* Creatinine level =< 1.2 x ULN or creatinine clearance > 60 mL/min/1.73 m^2 for patients with creatinine levels above or below the institutional normal\r\n* Hemoglobin (Hgb) >= 9 g/dl without transfusion or epoetin dependency (=< 7 days prior to assessment)\r\n* Absolute neutrophil count >= 1.5 x 10^9/L\r\n* Platelets >= 100 x 10^9/L\r\n* Albumin >= 2.5 g/dlXx_NEWLINE_xXBilirubin =< 2 times institutional upper limit of normal unless elevation is thought to be due to hepatic infiltration by AML, Gilbert’s syndrome, or hemolysis (assessed within 10 days prior to study day 0)Xx_NEWLINE_xXAdequate renal and hepatic function (creatinine ? 2.0 mg/dl, bilirubin ? 2.0 mg/dl, aspartate transaminase (AST) and alanine transaminase (ALT) ? 4X upper limit of normal range).Xx_NEWLINE_xXAlanine aminotransferase (ALT) (serum glutamate pyruvate [SPGT]) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (ULN); this will not apply to subjects with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physicianXx_NEWLINE_xXSerum creatinine ? 1.5 mg/dl, serum glutamate oxaloacetate transaminase (SGOT) and bilirubin ? 1.5 times upper limit of normalXx_NEWLINE_xXAST and ALT =< 2 x institutional upper limit of normalXx_NEWLINE_xXProthrombin time =< 1.5 x upper limit of normal (ULN) obtained within 14 days of first treatmentXx_NEWLINE_xXAt risk for hepatic or renal failure\r\n* Serum creatinine > 1.5 mg/dl\r\n* Serum bilirubin > 1.3 mg/ml\r\n* Albumin < 2.0 g/dL\r\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times upper normal limit\r\n* Any history of hepatic encephalopathy\r\n* Cirrhosis or portal hypertension\r\n* Clinically evident ascites (trace ascites on imaging is acceptable)Xx_NEWLINE_xXAST or ALT >= 3 x ULN (upper limit of normal)Xx_NEWLINE_xXBilirubin =< 1 .5 x upper limit of normal (ULN) unless elevation is thought to be due to Gilbert’s syndrome, hemolysis, or hepatic infiltration by the hematologic malignancyXx_NEWLINE_xXTransaminases (AST/SGOT and ALT/SGPT) ? 2.5 times upper limit of normalXx_NEWLINE_xXAST(SGOT)/ALT(SGPT) > 2.5 x institutional upper limit of normalXx_NEWLINE_xXCA125 less than or equal to 3 x upper limit of normal (ULN) confirmed within 2 weeks of randomization using a centralized laboratory assayXx_NEWLINE_xXProthrombin time (PT) =< 1.5 x institutional upper limit of normal (ULN)Xx_NEWLINE_xXSerum bilirubin =< 2 x upper limit of normal, unless proven to be due to disease involvementXx_NEWLINE_xXAdequate liver function as defined below: \r\n• Serum Bilirubin < 1.5 x upper limit of normal (ULN) for institution [Exception: Patients who have elevated serum bilirubin due to underlying Gilbert’s Syndrome or familial benign unconjugated hyperbilirubinemia are allowed.] \r\n• AST (SGOT) < 2.5 x upper limit of normal (ULN) for institution (or < 5.0 x ULN in presence of liver metastases) \r\n• ALT (SGPT) < 2.5 x upper limit of normal (ULN) for institution (or < 5.0 x ULN in presence of liver metastases)Xx_NEWLINE_xXTotal bilirubin =< 1.5 x upper limit of reference range ( < 3 x upper limit of reference range in patients with Gilbert’s disease)Xx_NEWLINE_xXTransaminases =< 2 x upper limit of normal (ULN) or if liver metastases were present, =< 3 x ULNXx_NEWLINE_xXELIGIBILITY CRITERIA- LYMPHODEPLETION/INFUSION OF tvs-CTL: Serum AST < 5 x institutional upper limit of normal (IULN)Xx_NEWLINE_xXDocumented bilirubin and hepatic transaminases of =< 2.5 x upper limit of normal (ULN)Xx_NEWLINE_xXADDITIONAL CRITERIA FOR STUDY CONTINUATION: AST and ALT =< 2 X upper level of normalXx_NEWLINE_xXAT THE TIME OF INFUSION: Bilirubin ? 3 x normalXx_NEWLINE_xXNormal cardiac function must be documented within 90 days prior to registration; result of ejection fraction must be above the normal limit of the institutionXx_NEWLINE_xXLiver function tests > 3 x upper limit of normalXx_NEWLINE_xXAdequate liver function with serum AST, ALT and bilirubin within the normal range at the time of crenolanib commencementXx_NEWLINE_xXAspartate transaminase (AST) =< 2.5 x upper limit of normal (ULN)Xx_NEWLINE_xXSerum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values less than or equal to 2.5 times the upper limit of normal; patients with elevations of ALT or AST up to 10 times the upper limit of normal may be considered for participation if such elevations are thought to be due to liver involvement by malignancy; however, in these latter patients, if AST/ALT do not decrease to less than or equal to 2.5 times the upper limit of normal after induction chemotherapy, eligibility for the transplant (research) phase will be at the discretion of the PIXx_NEWLINE_xXRESEARCH PHASE INCLUSION CRITERIA: In patients with suspected liver disease, AST and ALT must be =< 2.5 times institutional upper limit of normal (ULN)Xx_NEWLINE_xXSerum glutamic oxaloacetic transaminase (SGPT) < 5 x upper limit of normal; some patients with minor deviations may be accepted on protocol after discussion with the PIXx_NEWLINE_xXLiver function test (LFTs) =< 2 x upper limit of normalXx_NEWLINE_xXBiochemistry: Total bilirubin* ? institutional upper limit of normal Alkaline phosphatase ? 2.5 x institutional upper limit of normal AST(SGOT) and ALT(SGPT) ? 2.5 x institutional upper limit of normal Creatinine Clearance ? 40 ml/min * excluding Gilbert's syndrome Creatinine clearance to be measured directly by 24 hour urine sampling or as calculated by Cockcroft Formula: Females: GFR = 1.04 x (140-age) x weight in kg serum creatinine in ?mol/L Males: GFR = 1.23 x (140-age) x weight in kg serum creatinine in ?mol/LXx_NEWLINE_xXPART 2: Transaminases must be < 3 x the upper limit of normalXx_NEWLINE_xXResearch participant transaminases does not exceed 2 x normal limitXx_NEWLINE_xXELIGIBILITY CRITERIA AT TIME OF INFUSION OF GENETICALLY MODIFIED T CELLS\r\n* Research participants has undergone lymphodepletion\r\n* Pulmonary: not requiring supplemental oxygen or mechanical ventilation, oxygen saturation 90% or higher on room air\r\n* Cardiovascular: not requiring pressor support, no symptomatic cardiac arrhythmias, no acute coronary syndrome, or uncontrolled hypertension\r\n* Renal Function: calculated creatinine clearance (absolute value) of >= 50 mL/minute or creatinine < 2.0 mg/dl or < 2 times upper limit of normal for the research participant's age group\r\n* Liver Function: adequate liver function defined as total bilirubin =< 3.0 mg/dl\r\n* ALT and AST =< 5 times the institutional upper limits of normal\r\n* Neurological: research participant without clinically significant encephalopathy/new focal deficits\r\n* Infectious diseases: no clinical evidence of uncontrolled active infectious process\r\n* Research participant must be off all anti-leukemic drugs, with the exception of the lymphodepleting regimens, at least 7 days prior to CAR T cell infusionXx_NEWLINE_xXALT and AST =< 2.5 times the institutional upper limits of normal\r\n* Note: in the event a participant has elevated levels of liver enzymes possibly related to underlying disease/disease progression, the participant will still be considered eligibleXx_NEWLINE_xXLiver function criteria: AST and ALT =< 2.5 times the institutional upper limits of normalXx_NEWLINE_xXAST and ALT <5x upper limit of normalXx_NEWLINE_xXProthrombin time (PT) < 1.3 x upper limit of normal (ULN)Xx_NEWLINE_xXSerum bilirubin =< twice the upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) < 1.5 times upper limit of normal (alkaline phosphatase and AST cannot both exceed the upper limit of normal)Xx_NEWLINE_xXTransaminases > 5x upper limit of normal for ageXx_NEWLINE_xXPatients who test positive for hepatitis C (HepC) antibodies (Ab) are eligible provided all of the following criteria are met: bilirubin =< 2 x upper limit of normal; ALT/AST =< 3 x upper limit of normal; and clinical evaluation to rule out cirrhosisXx_NEWLINE_xXPatients must have adequate hepatic function as documented by a bilirubin ? 2 x the institutional upper limit of normal, an alkaline phosphatase ? 2 x the institutional upper limit of normal, and an SGOT and SGPT ? 2 x the institutional upper limit of normal all obtained within 14 days prior to enrollment.Xx_NEWLINE_xXRANDOMIZED PHASE II (ARMS K AND L): AST/ALT =< 2.5 x upper limit of normal (ULN), obtained within 2 weeks prior to registrationXx_NEWLINE_xXNewly diagnosed MCL: AST (SGOT) and ALT (SGPT) < 2 x upper limit of normal or < 5 x upper limit of normal if hepatic metastases are presentXx_NEWLINE_xXPROCUREMENT INCLUSION CRITERIA\r\n* Diagnosis of recurrent aggressive or indolent B-cell lymphoma or CLL, or newly diagnosed patients unable to receive or complete standard therapy OR diagnosis of relapsed/refractory aggressive B-cell lymphoma with a treatment plan that will include high dose therapy and autologous stem cell transplantation\r\n* CD19-positive tumor (result can be pending at this time)\r\n* Hemoglobin (Hgb) > 8.0\r\n* If pheresis required to collect blood:\r\n** Creatinine < 1.5 × upper limit normal\r\n** Aspartate aminotransferase (AST) < 1.5 × upper limit normal\r\n** Prothrombin time (PT) and activated partial thromboplastin time (APTT) < 1.5 × upper limit normal\r\n* Informed consent explained to, understood by and signed by patient/guardian (and donor, where applicable); patient/guardian given copy of informed consentXx_NEWLINE_xXAST less than 5 times the upper limit of normalXx_NEWLINE_xXBilirubin =< 2x upper limit of normalXx_NEWLINE_xXSerum glutamate pyruvate transaminase (SGPT) =< 2.5 x upper limit of normal (ULN) or 5 x ULN if related to MF or MDS/MPN associated liver infiltrationXx_NEWLINE_xXPatients with baseline troponin levels greater than the institutional limit of normalXx_NEWLINE_xXAdequate organ function defined as: bilirubin <2x upper limit of normal (ULN) (unless associated with Gilbert's syndrome), and ALT or AST <2.5x ULN.Xx_NEWLINE_xXSerum alanine transaminase (ALT) less than three times the upper limit of normal (Turnstile II)Xx_NEWLINE_xXPatients must have normal organ and marrow function as defined below: leukocytes > 3,000/mcL; absolute neutrophil count >1,500/mcL; platelets > 100,000/mcL, total bilirubin < or = 2.0 mg/dL. (Does NOT apply to patients with Gilbert's Syndrome); AST(SGOT)/ALT(SGPT) < 2.5 X institutional upper limit of normal (patients with liver involvement will be allowed < or = 5.0 X institutional upper normal limit) serum creatinine < 2.0 mg/dLXx_NEWLINE_xXAST/ALT ? 2.5 times upper limit of normal (ULN)Xx_NEWLINE_xXTotal serum bilirubin < 2 x upper limit normal (unless due to hemolysis, Gilbert’s syndrome, or ineffective erythropoiesis)Xx_NEWLINE_xXBlood urea nitrogen (BUN) less than 2 x upper limit of normalXx_NEWLINE_xXSerum bilirubin < 2 mg/dL upper limit of normal (unless due to Gilbert's disease; patient with this disease should have a right upper quadrant ultrasound evaluation before treatment)Xx_NEWLINE_xXBilirubin =< 1.5 fold the upper limit of normalXx_NEWLINE_xXLiver enzymes < 3 fold the upper limit of normalXx_NEWLINE_xXBilirubin =< 2.5 X the upper normal limit of institution's normal rangeXx_NEWLINE_xXPartial thromboplastin time (PTT) must be =< 2 X upper normal limit of institution's normal range; subjects on anticoagulant (such as coumadin) must have a PTT =< 5 X upper normal limit of institution's normal rangeXx_NEWLINE_xXCreatinine =< 2.0 mg/dL for patients over 18 years or =< 2.5 x institutional upper limit of normal (ULN) for age, measured prior to conditioning chemotherapyXx_NEWLINE_xXSerum amylase =< 1.5 x institutional upper limit of normalXx_NEWLINE_xXObtained =< 28 days prior to randomization:\r\nTotal bilirubin =< 1.5 x upper limit of normal (ULN)Xx_NEWLINE_xXELIGIBILITY CRITERIA FOR REGISTRATION: AST(SGOT)/ALT(SGPT) =< 2.0 x institutional upper limit of normal (within one week of registration if patient postop, otherwise within two weeks of registration)Xx_NEWLINE_xXPatients with creatinine > 2.5 times upper limit of normal unless felt to be related the underlying leukemia by the treating physician or hemolysis or Gilbert's diseaseXx_NEWLINE_xXLiver enzymes less than three times the upper limit of normalXx_NEWLINE_xXDirect bilirubin > 3x upper limit of normalXx_NEWLINE_xXAmylase =< 2 x upper limit of normalXx_NEWLINE_xXSerum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values >= 2.5 times the upper limit of normal based on age-specific normal values; if the abnormal liver function is attributable to liver involvement by malignancy, patients may be eligible with serum ALT and AST values up to 5.0 times the upper limit of normal, provided the patient has no evidence of impending hepatic failure (encephalopathy or prothrombin time > 2 times the upper limit of normal)Xx_NEWLINE_xXAlanine aminotransferase (ALT) < 3 x upper limit of normal unless benign congenital hyperbilirubinemiaXx_NEWLINE_xXTransaminases less than or equal 3 x upper limit of normal unless related to the diseaseXx_NEWLINE_xXSerum alanine aminotransferase (ALT) less than three times the upper limit of normal (Turnstile II - Chemotherapy/Cell Infusion- Inclusion Criteria)Xx_NEWLINE_xXLiver: transaminases < 5 x upper limit of normal and bilirubin < 3 x upper limit of normalXx_NEWLINE_xXLiver function: bilirubin > 1.5x upper limit of normal (ULN) and SGOT (AST) > 2.5x ULN.Xx_NEWLINE_xXserum CA-125 level ?2x upper limit of normal (ULN) (in screening)Xx_NEWLINE_xXBilirubin level above the normal reference rangeXx_NEWLINE_xXScreening Laboratory Values Hemoglobin ? 9g/dL White blood cell count ? 3,500 cells/mm3 Absolute neutrophil count ? 1,500 cells/mm3 Total bilirubin ? 2 times upper limit of normal Serum AST and ALT ? 2.5 times upper limit of normal Serum creatinine concentration ? 2mg/mL Pregnancy test: negative for females of childbearing potentialXx_NEWLINE_xXacute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase level 3 times or more and/or bilirubin level 2 times or more higher the upper limit of the normal range;Xx_NEWLINE_xXAST/SGOT and ALT/SGPT ?2.5×ULN. (upper limit of normal)Xx_NEWLINE_xXAspartate Transaminase (AST) / Alanine Transaminase (ALT) ? 3 times institutional upper limit of normal (except in patients with leukemic infiltration of liver)Xx_NEWLINE_xXAST/ALT ? 3 times institutional upper limit of normal (except in patients with leukemic infiltration of liver)Xx_NEWLINE_xXSerum SGOT/AST <3.0 x upper limits of normal (ULN)Xx_NEWLINE_xXSerum SGPT/ALT <3.0 x upper limits of normal (ULN)Xx_NEWLINE_xXSGOT (AST)<3x upper limit of normalXx_NEWLINE_xXEvidence of abnormal liver function (serum ALT level(s) > 5 times upper limit of normal at screening or creatinine levels >2 times upper limit of normal at screening);Xx_NEWLINE_xXHas the following laboratory parameters within 7 days before baseline (C1D1):Serum creatinine ?2 mg/dL; Total bilirubin ?2.0 mg/dL; Alanine transaminase (ALT) or aspartate transaminase (AST) <3.0×the upper limit of normal (ULN); Left ventricular ejection fraction (LVEF) >40%; Forced expiratory volume in 1 second (FEV1) >60% of predicted.Xx_NEWLINE_xXPatients with PT/PTT above the upper limit of normalXx_NEWLINE_xXPT and PTT < 1.25 times the institutional upper limit of normal.Xx_NEWLINE_xXAdequate hepatic function as documented by serum bilirubin< 1.5 mg/dl and SGOT and SGPT 1.5 or less x upper limit of normal.Xx_NEWLINE_xXALT (SGPT): < 2.5 X institutional upper limit of normalXx_NEWLINE_xXRenal insufficiency (creatinine clearance < 40 ml/min) or liver insufficiency (serum bilirubin > 2 times the upper normal range and/or serum transaminases (AST/SGOT, ALT/SGPT, but not gamma Glutamyl Transpeptidase) >3 times the upper normal range). Creatinine clearance may be calculated according to validated formulas (Crockoft's or MDRD)Xx_NEWLINE_xXAST and/or ALT ?2.5 times upper limit of normal (ULN)Xx_NEWLINE_xXAST & ALT ? 5 x the upper limit normalXx_NEWLINE_xXALT/AST <2.5 times the upper limit of normal (ULN)Xx_NEWLINE_xXtotal bilirubin: ?2 x upper normal limit (UNL) (patients with Gilbert's disease are eligible, hyperbilirubinemia is intermittent & indirect)Xx_NEWLINE_xXBilirubin ? 2.5 x institutional upper limit of normal (IULN) unless elevation is thought to be due to hepatic infiltration by AML, Gilbert’s syndrome, or hemolysis (assessed within 14 days prior to study day 0)Xx_NEWLINE_xXAdequate hepatic function (>= 1.5 x upper limit of normal [ULN]; patient’s with Gilbert’s disease are not excluded)Xx_NEWLINE_xXAST, ALT, and total bilirubin ? 3x upper limit of normal;Xx_NEWLINE_xXSGPT (ALT) and SGOT (AST) < 3 x upper limit of normal (for ALT, the upper limit of normal for all sites is defined as 45 U/L)Xx_NEWLINE_xXTransaminases must be < 3 x the upper limit of normal per reference values of treating institutionXx_NEWLINE_xXNon-fasting bilirubin =< 1.5 X the upper normal limit of institution's normal rangeXx_NEWLINE_xXDONORS: Hemoglobin within 10% of upper and lower limit of normal range of test (gender based for hemoglobin)Xx_NEWLINE_xXDONORS: Platelets within 10% of upper and lower limit of normal range of test (gender based for hemoglobin)Xx_NEWLINE_xXDONORS: ALT < 2 x upper limit of normalXx_NEWLINE_xXObtained within 28 days prior to registration: Alkaline phosphatase =< 2.5 x upper limit of normal, unless bone or liver metastasis is present (=< 5 x upper limit of normal)Xx_NEWLINE_xXLiver function tests > 3 x upper limit of normalXx_NEWLINE_xXAspartate transaminase (AST) =< 3 x upper limit of normal (ULN)Xx_NEWLINE_xXWithin 14 days prior to step 1 registration: Serum bilirubin =< 1.5 x institutional upper limit of normalXx_NEWLINE_xXSodium >= the institutional lower limit of normalXx_NEWLINE_xXTREATMENT: AST (SGOT)/ALT (SGPT) =< 3 x institutional upper limit of normalXx_NEWLINE_xXDOSE EXPANSION COHORT: AST(SGOT) ? 2.5 X institutional upper limit of normal (ULN)Xx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (ULN); (this will not apply to subjects with confirmed Gilbert’s syndrome [persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology], who will be allowed only in consultation with their physician)Xx_NEWLINE_xXNote: ULN is institutional or laboratory upper limit of normalXx_NEWLINE_xXTotal bilirubin =< 1.5 x upper limit of normal unless clearly related to Gilbert’s disease, hemolysis or leukemic infiltrateXx_NEWLINE_xXSerum glutamate pyruvate (SGPT) (alanine aminotransferase [ALT]) =< 3.0 x upper limit of normal (ULN) for age and institution (unless it is related to leukemic involvement)Xx_NEWLINE_xXSecondary Registration: AST (SGOT)/ALT (SGPT) =< 2.0 x institutional upper limit of normalXx_NEWLINE_xXPatients must have serum direct bilirubin =< 2.0 mg/dl and transaminases =< 3x institution upper limit of normalXx_NEWLINE_xXProthrombin time (PT) within 2 seconds of the upper limit of normal (ULN)Xx_NEWLINE_xXSubjects must have normal organ and marrow function as defined below:\n\n               1. Absolute neutrophil count ? 1500/cmm\n\n               2. Platelets ? 100,000/cmm\n\n               3. Total bilirubinwithin normal limits of the institution\n\n               4. AST/ALT ? 2.5 X institutional upper limit of normal (ULN) or ? 5 X institutional\n                  upper limit of normal (ULN) in the presence of liver metastases\n\n               5. Creatinine ? 1.5 X institutional upper limit of normal (ULN)Xx_NEWLINE_xXSerum bilirubin =< institutional upper limit of normal (IULN); for patients with liver metastases, bilirubin must be =< 5 x IULN obtained within 28 days prior to Step 2 re-registrationXx_NEWLINE_xXAt least one of the following clinical, laboratory, or imaging parameters:\r\n* Mild or moderate ascites\r\n* Serum bilirubin >= 3 mg/dl but less than 6 mg/dl\r\n* Aspartate aminotransferase (AST) > 5 times upper limit of normal (ULN) but =< 10 times ULN\r\n* Alanine aminotransferase (ALT) > 5 times upper limit of normal (ULN) but =< 10 times ULN\r\n* International normalized ratio for prothrombin time (INR) >1.5 but =< 2.5\r\n* Bland portal vein thrombosis (branch or main)\r\n* Functioning transjugular intrahepatic portosystemic shunt (TIPS) or surgical portosystemic shuntXx_NEWLINE_xXAST > 10 times upper normal limitXx_NEWLINE_xXALT > 10 times upper normal limitXx_NEWLINE_xXTransaminases < 2.5 x upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 × the upper normal limit of institution's normal range; for subjects with liver metastases, AST and ALT < 5 × the upper normal limit of institution's normal range AS LONG AS THERE IS NO persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophiliaXx_NEWLINE_xXNon-fasting direct bilirubin =< 1.5 × the upper normal limit of institution's normal rangeXx_NEWLINE_xXTransaminases < 5.0 x upper limit of normal (ULN)Xx_NEWLINE_xXPatients must have corrected calcium and phosphate < upper limit or normal (ULN) obtained within 7 days prior to sub-study registrationXx_NEWLINE_xXSerum bilirubin =< institutional upper limit of normal (IULN); for patients with liver metastases, bilirubin must be =< 5 x IULN within 28 days prior to Step 2 re-registrationXx_NEWLINE_xXSerum bilirubin =< institutional upper limit of normal (IULN); for patients with liver metastases, bilirubin must be =< 5 x IULN within 28 days prior to step 2 re-registrationXx_NEWLINE_xXTotal bilirubin =< upper limit of normal (or =< 1.5 x upper limit of normal if live metastases are present; or total bilirubin =< 3.0 x upper limit of normal with direct bilirubin within normal range in patients with well documented Gilbert’s syndrome, which is defined as presence of several episodes of unconjugated hyperbilirubinemia with normal results from complete blood count [CBC] count [including normal reticulocyte count and blood smear], normal liver function test results, and absence of other contributing disease processes at the time of diagnosis)Xx_NEWLINE_xXSerum amylase =< upper limit of normalXx_NEWLINE_xXDONOR: ALT < 2 x upper limit of normalXx_NEWLINE_xXWithin 14 days of subject registration: Total bilirubin within normal range or =< 1.5 X institutional upper limit of normal (IULN) if liver metastases are present or total bilirubin =< 3.0 X IULN with direct bilirubin within normal range in subjects with well-documented Gilbert’s syndrome, which is defined as presence of unconjugated hyperbilirubinemia with normal results from complete blood count (CBC) (including normal reticulocyte count and blood smear), normal liver function test results and absence of other contributing disease processes at the time of diagnosisXx_NEWLINE_xXAlanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) of the institutional normal reference rangeXx_NEWLINE_xXBilirubin < 1.5 x ULN of the institutional normal reference rangeXx_NEWLINE_xXAspartate amino transferase (AST) or alanine amino transferase (ALT) >= 2.5 times the upper limit of normal (if related to liver metastases >= five times the upper limit of normal)Xx_NEWLINE_xXWith hepatic dysfunction as evidenced by total bilirubin > 2.0 x upper limit of normal or evidence of synthetic dysfunction or severe cirrhosisXx_NEWLINE_xXWith hepatic dysfunction as evidenced by aspartate aminotransferase (AST) > 2.0 x upper limit of normal or evidence of synthetic dysfunction or severe cirrhosisXx_NEWLINE_xXAdequate hepatic function, with serum ALT ? 3times the upper limit of normal and\n             serum direct bilirubin ? 2 mg/dL (34 µmol/L) within 14 days prior to randomizationXx_NEWLINE_xXSerum ALT and AST less than three times the institutional upper limit of normalXx_NEWLINE_xXTransaminases < 2.5 x upper limit of normal (up to 5 x upper limit of normal [ULN] in patients with liver metastases)Xx_NEWLINE_xXTotal bilirubin =< 1.5 institutional upper limit of normal (ULN), unless elevated secondary to lymphomatous involvement of liver or biliary system, or due to other HIV medications (e.g., indinavir, tenofovir, or atazanavir); for direct bilirubin > 1.2 due to hepatic involvement by tumor for the initial dose of EPOCH drug adjustmentXx_NEWLINE_xXSerum bilirubin =< 1.5x upper limit of normalXx_NEWLINE_xXAST and ALT > 2 x upper limit of normalXx_NEWLINE_xXAST and ALT >= 2 x upper limit of normalXx_NEWLINE_xXCreatinine (non-isotope dilution mass spectrometry [IDMS]) =< 1.5 x institutional upper limit normal (ULN), CTCAE grade 1Xx_NEWLINE_xXSerum creatinine =< 2 x institutional upper limit of normal (IULN), unless due to lymphoma, within 42 day prior to registrationXx_NEWLINE_xXDysfunction of liver (ALT/AST > 5 times normal value, or bilirubin > 3 times normal value), or of renal function (creatinine clearance <30ml/min/1.73m2)Xx_NEWLINE_xXINR < 1.5 or PTT value < 1.5 x upper limit of normal (ULN) at study entryXx_NEWLINE_xXPerformed within 14 days of patient registration: Total bilirubin within normal range or =< 1.5 x institutional upper limit of normal (IULN) if liver metastases are present or total bilirubin =< 3.0 x IULN with direct bilirubin within normal range in patients with well documented Gilbert’s syndrome, which is defined as presence of several episodes of unconjugated hyperbilirubinemia with normal results from complete blood count (CBC) (including normal reticulocyte count and blood smear), normal liver function test results, and absence of other contributing disease processes at the time of diagnosisXx_NEWLINE_xXAST and ALT ? 2.5 times the upper limit of normal (ULN)Xx_NEWLINE_xXAST and ALT ? 2.5 times the upper limit of normal (ULN)Xx_NEWLINE_xXAST/ALT =< 3 X upper limit of normal (ULN)Xx_NEWLINE_xXAST (SGOT), ALT (SGPT) ? 2.5 x upper limit of normal (ULN),Xx_NEWLINE_xXSerum bilirubin =< institutional upper limit of normal (IULN) within 28 days prior to RE-TREATMENT registration; for patients with liver metastases, bilirubin must be =< 5 x IULNXx_NEWLINE_xXBilirubin* within normal rangeXx_NEWLINE_xXLiver function tests (LFTs) greater than twice the upper limit of normalXx_NEWLINE_xXSerum bilirubin < 1.5x upper limit of normalXx_NEWLINE_xXTransaminases < 3x upper limit of normalXx_NEWLINE_xXPatients must have a total bilirubin =< 2.0 x institutional upper limit of normal (IULN) within 14 days prior to registration, unless the elevation is due primarily to elevated unconjugated hyperbilirubinemia secondary to Gilbert’s syndrome or hemolysis and not to liver dysfunctionXx_NEWLINE_xXProthrombin Time or INR ?1.5x upper limit of normal (ULN) unless receiving therapeutic anticoagulation.Xx_NEWLINE_xXPT, PTT (in seconds) not to be prolonged beyond >20% of the upper limits of normal.Xx_NEWLINE_xXAST and ALT ? 5 times upper limit of normal (ULN)Xx_NEWLINE_xXCardiac Troponin I within normal limit.Xx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (IULN) OR serum bilirubin =< 3.0 x IULN for patients with Gilbert’s disease or documented hepatic involvement with non-Hodgkin lymphoma (NHL)Xx_NEWLINE_xXALT (SGPT) and/or AST (SGOT) ? 3x upper limit of normal (ULN), or ? 4 x ULN (if upon judgment of the treating physician, it is believed to be due to extramedullary hematopoiesis [EMH] related to MF);Xx_NEWLINE_xXTotal bilirubin > 1.5 x the upper limit of reference range (ULRR)Xx_NEWLINE_xXAST or ALT ? 3 x the institutional upper limit of normalXx_NEWLINE_xXALT and AST< 5 X upper limit of normalXx_NEWLINE_xXAspartate transaminase (AST) < 2.5 x upper limit of normal (ULN) and alanine transaminase (ALT) ? 2.5 × upper limit of normal (ULN).Xx_NEWLINE_xXSerum bilirubin < 2 x upper limit of normal, or considered not clinically significant by the study doctor or designeeXx_NEWLINE_xXPatients must have adequate organ and marrow function as defined below: NOTE: Institutional/laboratory upper limit of normal = ULN Institutional/laboratory lower limit of normal = LLNXx_NEWLINE_xXProthrombin time (PT) =< 1.5 times the upper limit of normalXx_NEWLINE_xXBilirubin =< 2.0 x the institutional normal upper limit unless secondary to bile duct obstruction by tumorXx_NEWLINE_xXBilirubin =< 2.5 x institutional upper limit of normal (IULN) unless elevation is thought to be due to hepatic infiltration by AML, Gilbert’s syndrome, or hemolysis (assessed within 14 days prior to study day 0)Xx_NEWLINE_xXAST/ALT > 3 x upper limit of normalXx_NEWLINE_xXAdequate coagulation defined as:\r\n* Prothrombin time (PT) =< 1.2 x upper limit of normalXx_NEWLINE_xXAST/ALT ? 3X ULN (upper limit of normal)Xx_NEWLINE_xXAST/ALT =< 2 x upper limit of normal (ULN)Xx_NEWLINE_xXAST =< 5 x upper limit of normalXx_NEWLINE_xXSerum AST and ALT ? 2.5 x Institutional upper limit of normal (ULN)Xx_NEWLINE_xXAdequate biochemistry laboratory results (AST/SGOT and ALT/SGPT ? 3.0 x upper limit of normal; bilirubin ? 2.0 mg/dL; creatinine clearance of ? 40 mL/min).Xx_NEWLINE_xXAspartate aminotransferase =< 3 x institutional upper limit of normal (ULN), obtained =< 21 days prior to registration and confirmed prior to the first dose of study drugXx_NEWLINE_xXAlanine aminotransferase =< 3 x institutional upper limit of normal (ULN), obtained =< 21 days prior to registration and confirmed prior to the first dose of study drugXx_NEWLINE_xXPartial thromboplastin time =< 1.66 times upper limit of normalXx_NEWLINE_xXUncompensated hypothyroidism (defined as thyroid-stimulating hormone [TSH] greater than 2 x upper limit of normal not treated with replacement hormone)Xx_NEWLINE_xXPatients must have adequate organ and bone marrow function prior to registration, as defined below: \r\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2 x institutional upper         limit of normal (IULN)\r\n* Total bilirubin < 2.0 x IULN (unless Gilbert syndrome has been diagnosed); if leukemia infiltration of the liver is suspected to be causing liver function abnormalities the patient will still be eligible with principal investigator (PI) approval\r\n* Creatinine < 2 x IULN\r\n* Creatinine clearance > 40 mL/min (measured by Cockroft-Gault)Xx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (ULN); (unless Gilbert's syndrome, without concurrent clinically significant liver disease), obtained within 14 days prior to first treatmentXx_NEWLINE_xXLiver transaminases > 5-times the upper limit of normalXx_NEWLINE_xXMeasurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of >= 2 times the upper limit of normal is requiredXx_NEWLINE_xXWithin 4 weeks of administration of study therapy: Lactate dehydrogenase (LDH) < 4 x upper limit of normal (ULN)Xx_NEWLINE_xXMeasurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of > 2 times the upper limit of normal of each institution is requiredXx_NEWLINE_xXThe direct bilirubin must be within normal parametersXx_NEWLINE_xXCreatine kinase (CK) =< 2.5 times the upper limit of normalXx_NEWLINE_xXLiver enzymes =< 2 times the upper limit of normalXx_NEWLINE_xXSerum amylase =< upper limit of normalXx_NEWLINE_xXAlkaline phosphates must be =< 2.5 X the upper limit of normalXx_NEWLINE_xXPHASE II: AST (SGOT)/ALT (SGPT) =< 2.5 x institutional upper limit of normalXx_NEWLINE_xXAdequate liver function defined as bilirubin =< 1.5 x upper limit of normal and alanine aminotransferase (ALT) =< 2.5 x upper limit of normalXx_NEWLINE_xXTotal bilirubin =< 1.5 x ULN (upper limit of normal), unless the patient meets the criteria for Gilbert’s syndrome; the upper limit value for bilirubin for subjects with Gilbert’s syndrome is less than 3 mg/dl\r\n* Note: A diagnosis of Gilbert’s disease will be made in the presence of (1) unconjugated hyperbilirubinemia noted on several occasions; (2) normal results from complete blood cell (CBC) count, reticulocyte count, and blood smear; (3) normal liver function test results; and (4) an absence of other disease processes that can explain the unconjugated hyperbilirubinemiaXx_NEWLINE_xXPlanning to receive autologous HCT per institutional standards as part of standard of care. Eligibility for autologous HCT should be based on institutional guidelines. However, at minimum all patients must meet the following criteria:\r\n* Karnofsky performance status (KPS) greater than 70\r\n* Cardiac left ventricular ejection fraction of greater than 40%\r\n* Calculated creatinine clearance of greater than 40 cc/min\r\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) of less than 2 x upper limit of normal\r\n* Direct bilirubin of less than 2 x upper limit of normalXx_NEWLINE_xXSerum total bilirubin ?1.5 × upper limit of normal (ULN), unless considered due to Gilbert's disease, a gene mutation in UGT1A1, or leukemic organ involvement, following approval by the Medical Monitor;Xx_NEWLINE_xXBilirubin less than or equal 1.5 x upper limit of normal (ULN) except for unconjugated hyperbilirubinemia or Gilbert's syndromeXx_NEWLINE_xXBaseline testosterone >= lower limit of normalXx_NEWLINE_xXPatients with baseline troponin levels greater than the institutional limit of normalXx_NEWLINE_xXTotal bilirubin =< 1.5 x upper limit of normal if no biliary stenting has been done; OR 2.0 x upper limit of normal if patient is status post (s/p) biliary stenting; OR two downtrending valuesXx_NEWLINE_xXObtained =< 7 days prior to registration: Serum amylase =< 1.5 x upper limit of normal (ULN)Xx_NEWLINE_xXPatients must have WBC >/= 3.5 x 10^9/L, ANC >/= 1.5 x 10^9/L, platelets >/= 100 x 10^9/L, Hb >/= 9.0 g/dL); total bilirubin </= 1.5 x ULN, AST and ALT </= 1.5 x the upper limit of normal; serum potassium of >/= 3.5 mEq/L, serum albumin of >/= 3.0 g/dL, serum creatinine </= 1.5 x ULNXx_NEWLINE_xXMagnesium at or above lower limit of normal (correction with supplements is fine as long as the resultant level is at or above the lower limit of normal)Xx_NEWLINE_xXPhosphorus at or above lower limit of normal (correction with supplements is fine as long as the resultant level is at or above the lower limit of normal)Xx_NEWLINE_xXTotal bilirubin =< the institutional upper limit of normal (exception permitted in patients with Gilbert’s syndrome after discussion with study principal investigator [PI], on a case by case basis and if liver function tests are within normal limits)Xx_NEWLINE_xXDirect bilirubin =< 1.5 upper limit of normal (ULN) age unless elevation thought to be due or hepatic infiltration by the hematologic malignancyXx_NEWLINE_xXSGOT(AST) and SGPT(ALT) < 3 x ULN (upper limit of normal)Xx_NEWLINE_xXTransaminases must be < 3 x the upper limit of normal per reference values of referring institutionXx_NEWLINE_xXTransaminase > 3 x upper normal limit (UNL)Xx_NEWLINE_xXALT > 2.0 times upper normal limit (unless due to chronic GVHD)Xx_NEWLINE_xXAST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normalXx_NEWLINE_xXPatients must have the following clinical laboratory values unless considered due to leukemic organ involvement: 1. Serum creatinine </= 2.0 mg/dl. 2. Total bilirubin </= 1.5x the upper limit of normal unless considered due to Gilbert's syndrome. 3. Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) </= 3x the upper limit of normal.Xx_NEWLINE_xXDONOR: ALT < 2 x upper limit of normalXx_NEWLINE_xXLipase < 1.5 x the upper limit of normal (except for participants with adenocarcinoma of the pancreas)Xx_NEWLINE_xXAST(SGOT)/ALT(SGPT) ? 2.5 X institutional upper limit of normalXx_NEWLINE_xXPatients who test positive for hepatitis C antibody (Ab) are eligible provided all of the following criteria are met: 1) total bilirubin =< 2 x upper limit of normal; 2) AND aspartate aminotransferase (AST) =< 3 x upper limit of normal; AND 3) liver biopsy (pathology) demonstrates =< grade 2 fibrosis and no cirrhosisXx_NEWLINE_xXTransaminases < 3 times the upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 × the upper normal limit of institution's normal range; for subjects with liver metastases, AST and ALT < 5 × the upper normal limit of institution's normal range are acceptable AS LONG AS THERE IS NO persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia; the combination of 5-FU and oxaliplatin is known to be safe to be administered in patients with such abnormal liver function testsXx_NEWLINE_xXNon-fasting direct bilirubin =< 1.5 × the upper normal limit of institution's normal range; for subjects with liver metastases, non-fasting direct bilirubin > 1.5-3.0 x the upper normal limit of institution's normal range are acceptable AS LONG AS THERE IS NO persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia; the combination of 5-FU and oxaliplatin is known to be safe to be administered in patients with such abnormal liver function testsXx_NEWLINE_xXTotal bilirubin =< 5 x upper limit of normal if patient is s/p biliary stenting AND decreasing at least two time points after stentingXx_NEWLINE_xXPlasma creatine phosphokinase (CK) < 1.5 x upper limit of normal (ULN)Xx_NEWLINE_xXWithin 14 days prior to registration: Bilirubin =< 1.5 x upper limit of normal rangeXx_NEWLINE_xXWithin 14 days prior to registration: Blood urea nitrogen (BUN) =< 1.5 x upper limit of normal rangeXx_NEWLINE_xXserum aspartate transaminase or alanine transaminase > 3x upper limit of normal (ULN), except in patients with documented liver involvement by lymphomaXx_NEWLINE_xXSerum bilirubin =< 1.5 x upper limit of normal (ULN) unless deemed elevated secondary to lymphoma involvement of the liver or known Gilbert's syndromeXx_NEWLINE_xXMeets criteria for poor-risk defined as 3 or more of the following: ECOG performance status 2, anemia (hemoglobin lower than reference range), elevated serum lactate dehydrogenase (LDH) > 1.5 x upper limit of normal (ULN), hypercalcemia (corrected serum calcium level > upper limit of normal), time from initial RCC diagnosis to registration on this trial < 1 year, and > 1 metastatic organ sitesXx_NEWLINE_xXLiver function tests (LFT's) =< 5 x upper limit of institutional normal (ULN)Xx_NEWLINE_xXAST(SGOT)/ALT(SGPT) ? 2.5 X institutional upper limit of normalXx_NEWLINE_xXCreatinine phosphokinase (CPK) within 2.5 x upper limit of normal (CTCAE 4.0 grade 1 abnormality is acceptable)Xx_NEWLINE_xXTransaminases =< 5 x the upper limit of normal for age appropriate indicesXx_NEWLINE_xXAdequate liver function, as evidenced by total serum bilirubin =< 1.5 times the upper limit of normal (patients with Gilbert’s disease are eligible, provided intermittent indirect hyperbilirubinemia)Xx_NEWLINE_xXPart A: Serum alpha fetoprotein greater than or equal to 1.5 Upper Limits of Normal, Part B: Serum alpha fetoprotein less than 1.5 Upper Limits of Normal. Not applicable for Part C or DXx_NEWLINE_xXNormal pancreatic functionXx_NEWLINE_xXEXPANSION COHORT ONLY: AST (SGOT)/ALT (SGPT) =< 2.5 X institutional upper limit of normalXx_NEWLINE_xXSerum SGOT/AST <3.0 x upper limits of normal (ULN)Xx_NEWLINE_xXSerum SGPT/ALT <3.0 x upper limits of normal (ULN)Xx_NEWLINE_xXAST =< 2 x upper limit of normalXx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (ULN); this will not apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physicianXx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (ULN); this will not apply to patients with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology)Xx_NEWLINE_xXPatients must have normal organ and marrow function as defined below: leukocytes >3,000/mcL; absolute neutrophil count >1,500/mcL; platelets >100,000/mcL; total bilirubin <1.5 X institutional upper limits of normal; AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal; Alkaline phosphatase (AP) <2.5 X institutional upper limit of normal; creatinine <1.5X institutional upper limit of normal OR creatinine clearance >50 mL/min/1.73 m2 for patients with creatinine levels above institutional normalXx_NEWLINE_xXBlood urea nitrogen (BUN) < 1.5 times upper limit of laboratory normalXx_NEWLINE_xXRenal Function: Patients must have serum creatinine ? 1.5 times upper limit of institutional normal for age and/or GFR ? 70 mL/min/1.73 m2.Xx_NEWLINE_xXPatients must have adequate bone marrow function (ANC = or > 1,500/mm^3 and platelet count of = or > 100,000/mm^3), adequate liver function (SGPT = or < 3 times upper limit of normal and alkaline phosphatase = or < 2 times upper limit of normal, bilirubin = or <1.5 mg/dl), adequate renal function (BUN and creatinine = or <1.5 times upper limit of normal) and normal serum amylase and lipase prior to starting therapy. Elevated cholesterol and triglycerides are not a contraindication to study enrollment, but should be managed as clinically appropriate by the treating physician.Xx_NEWLINE_xXSerum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values less than or equal to 2.5 times the upper limit of normal; patients with elevations of ALT or AST up to 10 times the upper limit of normal may be considered for participation if such elevations are thought to be due to liver involvement by malignancy; however, in these latter patients, if these values do not decrease to less than or equal to 2.5 times the upper limit of normal during induction chemotherapy, such patients will not be eligible for the transplant phase of the protocol, and will thus be taken off studyXx_NEWLINE_xXPatients must have a direct bilirubin < 1.5 x upper limit of normal (ULN) for age or normal; these criteria may be waived for patients with known or suspected liver involvement by leukemia following review and approval by the study chair or vice chairXx_NEWLINE_xXAST or ALT greater than 5 times upper limit of normal or greater than 250 U/l.Xx_NEWLINE_xXActive hepatitis or liver biopsy evidence of cirrhosis or periportal fibrosis; liver function tests: total bilirubin > 2 x the upper limit of normal and/or serum glutamic pyruvate transaminase (SGPT) and SGPT > 4 x the upper limit of normalXx_NEWLINE_xXBilirubin less than or equal to 1.5 x upper limit of normal, CTCAE v 4.0 grade 1Xx_NEWLINE_xXAspartate transaminase (AST) less than or equal to 2.5 x upper limit of normal, CTCAE v 4.0 grade 1Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x upper limit of normal, unless liver is involved with disease or a history of Gilbert’s diseaseXx_NEWLINE_xXAdequate renal function [creatinine ? 1.5x ULN (upper limit of normal)] or GFR of ? 60mL/min.Xx_NEWLINE_xXTotal bilirubin =< 1.5 x upper limit of normal (ULN) unless elevation is deemed due to leukemia infiltration; in these patients, dose modification may be required based on standard guidelinesXx_NEWLINE_xXPatient's ALT and AST must be < 5 x institutional upper limit of norm ULN. The hepatic requirements are waived for patients with known or suspected liver involvement who would otherwise be eligible after consultation with the Study Chair or Vice Chair.Xx_NEWLINE_xXAST(SGOT)/ALT(SGPT) <1.5 X institutional upper limit of normalXx_NEWLINE_xXSerum bilirubin =< 2 x the laboratory normal range (except for patients with Gilbert’s disease)Xx_NEWLINE_xXTransaminases > 3 times upper normal limitXx_NEWLINE_xXHepatic function\r\n* ARM A:\r\n** Liver enzymes (< x 3 upper limit of normal [ULN]),\r\n** Bilirubin (< x 2 ULN) and stable in the 30 days prior to TCD boost\r\n* ARM B: No limitationXx_NEWLINE_xXMust have measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of ? 2 times the upper limit of each institution's normal value is required.Xx_NEWLINE_xXSerum total bilirubin ? 2.0 mg/dL (34.2 ?mol/L); or > 3.0 × upper limit of normal (ULN) for subjects with hereditary benign hyperbilirubinemiaXx_NEWLINE_xXCreatinine =< 2 x upper limit of normal, unless there is known chronic kidney disease (CKD) (creatinine must be at baseline for subjects with chronic kidney disease)Xx_NEWLINE_xXPOST-TRANSPLANT ELIGIBILITY CRITERIA:\r\n* In complete remission (CR) (including incomplete blood count recovery [CRi] and marrow CR) on bone marrow biopsy for response assessment after HCT (typically day +30)\r\n* Patient is within 30-100 days after HCT\r\n* Absolute neutrophil count (ANC) >= 1000/uL, platelet count >= 20,000/uL\r\n* ECOG performance status 0-2\r\n* Adequate major organ function, as defined by AST and ALT =< 2 x upper limit of normal\r\n* Total serum bilirubin < 2 x upper limit of normal (unless due to hemolysis or Gilbert’s syndrome, then no upper limit)\r\n* Creatinine =< 2 x upper limit of normal unless there is known chronic kidney disease (CKD) (creatinine must be at baseline for subjects with CKD)\r\n* In agreement to use an effective barrier method of birth control to avoid pregnancy during the study and for a minimum of 30 days after study treatment, for all male and female patients who are fertileXx_NEWLINE_xXAST or ALT > 2 x upper limit of normalXx_NEWLINE_xXPOST-TRANSPLANT EXCLUSION CRITERIA:\r\n* Active grade II-IV acute graft versus host disease (GVHD)\r\n* Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy\r\n* Serum creatinine > 2 x upper limit of normal unless there is known CKD (creatinine must be at baseline for subjects with CKD)\r\n* AST or ALT > 2 x upper limit of normal\r\n* Total bilirubin > 2 x upper limit of normal\r\n* History of psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consent\r\n* Pregnancy\r\n* Concurrent use of any other investigational agents on a clinical trial\r\n* Known hypersensitivity to 5-azacytidine\r\n** Prior treatment with 5-azacytidine is allowedXx_NEWLINE_xXSodium >= 130 mg/dl and =< upper limit of normalXx_NEWLINE_xXPotassium >= 3.0 mg/dl and =< upper limit of normalXx_NEWLINE_xXAdequate baseline organ function defined by the criteria below: total bilirubin =< 1.5x the upper limit of normal (ULN) except for Gilbert's syndrome or cases clearly not indicative of inadequate liver function (i.e. elevation of indirect [haemolytic] bilirubin in the absence of alanine aminotransferase [ALT] abnormality); ALT =< 2.5xULN; creatinine =< 2.5xULNXx_NEWLINE_xXAlkaline phosphatase < 2.5 times the upper limit of normal; in patients with liver metastasis, liver function tests should be < 5 times the upper limit of normalXx_NEWLINE_xXBlood urea nitrogen (BUN) < 2.5 times the upper limit of normalXx_NEWLINE_xXSerum bilirubin =< 1.5 x upper limit of normal (ULN) unless elevation is considered to be secondary to Gilbert’s syndrome, hemolysis, or hepatic infiltration by AMLXx_NEWLINE_xXAST/ALT ? 5 X upper limit of normalXx_NEWLINE_xXAlkaline phosphatase < 2.5 x institutional upper limit of normal (in subjects with no liver metastasis and < 5.0 upper limit of normal [ULN] in subjects with liver metastasis)Xx_NEWLINE_xXTREATMENT: Prothrombin time (PT) within 2 seconds of the upper limit of normal (ULN)Xx_NEWLINE_xXDONOR: ALT < 2 x upper limit of normalXx_NEWLINE_xXHepatic insufficiency (> 1.5 times the upper normal limit of transaminase levels)Xx_NEWLINE_xXNON-PROGRESSED DIPG (STRATUM 2): ALT(SGPT) =< 3 x institutional upper limit of normalXx_NEWLINE_xXCreatine phosphokinase =< institutional upper limit of normalXx_NEWLINE_xXAST and ALT ?3 x upper limit of normalXx_NEWLINE_xXSerum bilirubin levels =< 1.5 times the upper limit of the normal (ULN) range for the laboratory; higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesisXx_NEWLINE_xXAspartate transaminase (SGOT) must be less than 3x institutional upper limit of normal.Xx_NEWLINE_xXSerum creatinine level > 1.5 x the upper limit of normal (ULN), chronic renal failure requiring hemodialysis or peritoneal dialysis.Xx_NEWLINE_xXDocumentation of mucin 16 (MUC16) expression by either serum carcinoma antigen 125 (CA125) >=2 x Upper limit of normal (ULN) or by immunohistochemistry [IHC] by central reviewXx_NEWLINE_xXSGPT < 2X upper limit of normal.Xx_NEWLINE_xXElectrolyte abnormality that has not responded to correction, including hypokalemia or hypocalcemia less than the lower limit of normal, or hyperkalemia or hypercalcemia greater than the upper limit of normal (ULN).Xx_NEWLINE_xXTotal bilirubin =< 1.5 x institutional upper normal limit (UNL) or =< 3 x institutional UNL if known Gilbert’s syndromeXx_NEWLINE_xXTotal bilirubin =< 5 x upper limit of normal AND decreasing at least two time points if patient is s/p biliary stentingXx_NEWLINE_xXLiver dysfunction: aspartate transaminase, alanine aminotransferase increase ?2-fold above the upper-limit of local lab normal ranges.Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 X the upper normal limit of institution's normal range; for subjects with liver metastases, AST and ALT < 5 X the upper normal limit of institution's normal range AS LONG AS THERE IS NO persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophiliaXx_NEWLINE_xXNon-fasting bilirubin =< 1.5 X the upper normal limit of institution's normal range; non-fasting bilirubin 1.5 - 3.0 X the upper normal limit of institution's normal range are acceptable AS LONG AS THERE IS NO persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophiliaXx_NEWLINE_xXPatient's ALT must be < 5 x institutional upper limit of norm ULN.Xx_NEWLINE_xXNo evidence of coagulopathy as indicated by prothrombin time (PT) =< 1.5 X upper limit of normalXx_NEWLINE_xXAlkaline phosphatase =< 2.5 X upper limit of normal in the absence of liver or bone metastasis, or =< 5.0 x upper limit of normal range if bone or liver metastasesXx_NEWLINE_xXSerum creatinine >1.5 x ULN or calculated or directly measured CrCl < 50% lower limit of normalXx_NEWLINE_xXAspartate amino transferase (AST) or alanine amino transferase (ALT) >= three (3) times the upper limit of normalXx_NEWLINE_xXSerum glutamate pyruvate transaminase (SGPT) equal to or less than 3 x upper limit of normal (unless considered to be related to MF or patient has known history of Gilberts)Xx_NEWLINE_xXLVEF above the institution's lower limit of normalXx_NEWLINE_xXParticipants with normal hepatic function: Total bilirubin and alanine aminotransferase (ALT) must be ? upper limit of the normal range (ULN).Xx_NEWLINE_xXAdequate baseline organ function defined as: absolute neutrophil count >= 1.2 x 10^9/Liter (L); hemoglobin>=9 gram per deciliter (g/dL); platelets >= 75 x 10^9/L; prothrombin time /international normalized ratio and partial thromboplastin time =<1.3 x ULN; serum bilirubin=<1.5 times upper limit of normal (ULN); aspartate aminotransferase and alanine aminotransferase =<2.5 times ULN; serum creatinine=<1.5 mg/dL or calculate creatinine clearance >= 50 milliliter per minute; Left ventricular ejection fraction>= lower limit of normal by echocardiography.Xx_NEWLINE_xXSerum aspartate transaminase (AST) =< 2.5 x upper limit of normalXx_NEWLINE_xXSerum alanine transaminase (ALT) =< 2.5 x upper limit of normalXx_NEWLINE_xXLiver function tests less than 2 x upper limit of normal range (unless related to medications or Gilbert’s disease)Xx_NEWLINE_xXHepatic function: AST and ALT ? 2.5 × the upper normal limit of institution's normal range. For subjects with liver metastases, AST and ALT ? 5 × the upper normal limit of institution's normal range;Xx_NEWLINE_xXBilirubin: ? 1.5 × the upper normal limit of institution's normal range.Xx_NEWLINE_xXBilirubin < 2.0 mg/mL x upper limit of normal; this requirement reflects the excretion of CPX-351 by the liverXx_NEWLINE_xXSerum chromogranin A level >5 x upper limit of normal and/or serum neuron specific enolase (NSE) >2x upper limit of normalXx_NEWLINE_xXAST (SGOT) ? 2.5 x upper limits of normalXx_NEWLINE_xXALT (SGPT) ? 2.5 x upper limits of normalXx_NEWLINE_xXSubjects have adequate bone marrow, renal, and hepatic function as follows: Bone marrow: Absolute neutrophil count (ANC) >/= 1,500/mm3 Platelets >/= 100,000/mm3; Hemoglobin >/= 9.0 g/dL Renal function: Serum creatinine </= 1.5 times the upper limit of the institution's normal range Hepatic function: Bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) </= 1.5 times the upper limit of the institution's normal range. Subjects with liver metastasis may have an AST and ALT of </= 5.0 x the upper limit of normal.Xx_NEWLINE_xXAlanine transaminase (ALT), Aspartate transaminase (AST), or Creatine kinase (CK) greater than 2 times the upper limit of normalXx_NEWLINE_xXBilirubin =< 2 x institutional upper limit of normal (IULN) unless elevation is thought to be due to hepatic infiltration by AML, Gilbert’s syndrome, or hemolysis (assessed within 7 days prior to study day 1)Xx_NEWLINE_xXLDH < 1.50 X institutional upper limit of normalXx_NEWLINE_xXALT or AST ? twice the upper limit of normal (ULN), unless considered due to organ leukemic involvement;Xx_NEWLINE_xXAST, SGOT, ALT, SGPT ? 2.5 X upper limit of normal, < 5 upper limit if there are liver metastasesXx_NEWLINE_xXCoagulation Prothrombin time ? 1.5 X upper limitXx_NEWLINE_xXINR and aPTT < 1.2 times upper limit of normal for age.Xx_NEWLINE_xXLactate dehydrogenase (LDH) ? 2 times the upper limit of normal (ULN).Xx_NEWLINE_xXPhosphorus >= institutional lower limit of normal (repletion allowed)Xx_NEWLINE_xXAST and ALT </= 3x the upper limit of normalXx_NEWLINE_xXPT and aPTT each < 1.5 times the upper limit of normal.Xx_NEWLINE_xXALT < 2.5 X institutional upper limit of normalXx_NEWLINE_xXAST < 2.5 X institutional upper limit of normalXx_NEWLINE_xXAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 5 X institutional upper limit of normal OR a stable or a decreasing test value in patients who have undergone placement of an intrabiliary stent; both the treating radiation oncologist and medical oncologist must agree that the potential subject’s test value is acceptable for study accrualXx_NEWLINE_xXDonor must have adequate hepatic function as defined by a total bilirubin <3x upper limit of normal.Xx_NEWLINE_xXRecipient must have adequate hepatic function as defined by a total bilirubin <3x upper limit of normal or absence of hepatic fibrosis/cirrhosis.Xx_NEWLINE_xXAdequate organ function as evidenced by the following peripheral blood counts or serum chemistry values: hemoglobin 9 gram per deciliters (g/dL), absolute neutrophil count (ANC) 1,500/L, platelet count 100,000/L, serum creatinine 1.5*the upper limit of normal (ULN), creatine phosphokinase (CPK) 2.5 Upper Limit of Normal [ULN]Xx_NEWLINE_xXPatient has adequate hepatic function (serum bilirubin values <2.0 mg/dL and ALT and/or AST values <3 × the upper limit of normal ULN).Xx_NEWLINE_xXTotal bilirubin < 1.5 x upper limit of reference range (ULRR), unless the patient meets the criteria for Gilbert’s syndromeXx_NEWLINE_xXAdequate hepatic function, with serum ALT ? 3.5 times the upper limit of normal and serum direct bilirubin ? 2 mg/dL (34 µmol/L) within 21 days prior to randomizationXx_NEWLINE_xXNormal liver function based on Liver Function Tests (Total Bilirubin and AST <1.5 X Upper Limit of Normal).Xx_NEWLINE_xXALT and AST > 2.5 X upper limit of normalXx_NEWLINE_xXBaseline LVEF ? 50% and not lower than the institutional lower limit of normal;Xx_NEWLINE_xXSerum aspartate transaminase (AST) and serum alanine transaminase (ALT) =< 2.5 x upper limit of normal (< 5 X upper limit of normal [ULN] for subjects with liver metastasis)Xx_NEWLINE_xXSerum SGOT/AST or SGPT/ALT > 3.0 x upper limit of normal (ULN)Xx_NEWLINE_xXSGOT (AST) < 3x upper limit of normal.Xx_NEWLINE_xXSerum bilirubin greater than 1.25 times the upper limit of reference range (ULRR).Xx_NEWLINE_xXSerum transaminase (alanine aminotransferase [ALT]) equal to or =< 3 times the upper limit of the normal rangeXx_NEWLINE_xXHepatic: serum bilirubin less than 2x upper limit of normal for age as per local laboratory) (with the exception of isolated hyperbilirubinemia due to Gilbert's syndrome), alanine transaminase (ALT) and aspartate transaminase (AST) less than 4x upper limit of normal for age (as per local laboratory)Xx_NEWLINE_xXAST/ALT =< 2.5 x upper limit of normal (ULN)Xx_NEWLINE_xXProthrombin time (PT) =< 1.5 times upper limit of laboratory normal (ULN)Xx_NEWLINE_xXAspartate transaminase (AST) =< 3 x upper limit of normal (ULN)Xx_NEWLINE_xXPatients must have no signs of significant rhabdomyolysis determined by creatine phosphokinase (CPK) levels with a creatine kinase (CK) < 5 times the upper limit of normalXx_NEWLINE_xXSerum bilirubin =< 1.5 x institutional upper limit of normal (ULN); this will not apply to subjects with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician and the study principal investigator (PI)Xx_NEWLINE_xXProthrombin time (PT) no more than 2 seconds above the upper limit of normal (ULN)Xx_NEWLINE_xXSerum bilirubin < 1.5 x upper limit of normal (ULN) (maximum level based on MD Anderson laboratory ranges is 1.95 mg/dL)Xx_NEWLINE_xXProthrombin time (PT) =< 1.5 times upper limit of laboratory normal (ULN)Xx_NEWLINE_xXCreatine phosphokinase (CPK) =< the institutional upper limit of normalXx_NEWLINE_xXLVEF that is ?50% (or ? institutional lower limit of normal);Xx_NEWLINE_xXRenal insufficiency, defined as creatinine level greater than the upper limit of normal for ageXx_NEWLINE_xXDirect bilirubin 5 x upper limit of normal (based on institutional standards)Xx_NEWLINE_xXObtained =< 30 days prior to registration: Serum creatinine =< 1.5 times the institutional upper limit of normal (ULN); NOTE: can be waived with permission of study chair (documentation such as an email must be provided)Xx_NEWLINE_xXAlk phosphatase =< 3 times institutional upper limit of normalXx_NEWLINE_xXPatients must not have elevated liver transaminase levels; adequate liver function is defined as total bilirubin =< 1.5 times upper limit of normal, serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 5 times upper limit of normal and serum albumin >= 2 g/dLXx_NEWLINE_xXTotal (T.) bilirubin > 2 x upper limit of normal or alanine aminotransferase (ALT) > 4 x upper limit of normal or unresolved veno-occlusive diseaseXx_NEWLINE_xXBlood urea nitrogen (BUN) within 1.5 times the institutional upper limit of normal (ULN) (e.g., if the ULN is 20 mg/dL, then BUN up to 30 mg/dL is permitted)Xx_NEWLINE_xXAlanine aminotransaminase (ALT) < 5 x upper limit of normal (ULN)Xx_NEWLINE_xXMeasurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of > 2 times the upper limit of normal of each institution is requiredXx_NEWLINE_xXParticipants with non-evaluable or non-measurable cancer are eligible if they have a confirmed increase in tumor antigens >=2 x upper limit of normal (ULN).Xx_NEWLINE_xXAST < 3 times upper limit of normal (alkaline phosphatase and AST cannot both exceed the upper limit of normal)Xx_NEWLINE_xXSerum creatinine must be < 1.5 times the upper limit of the institutional normal range; test results must be no more than 3 months oldXx_NEWLINE_xXBilirubin > 5 x upper limit of normal if documented in the last month and not lowered to < 5 x normal prior to study enrollment; extra blood work will not be drawn unless the patient already has the lab abnormalities documented and need to be correctedXx_NEWLINE_xXMinocycline trial only: patients with adequate renal function according to MD Anderson testing standards (screening cut off for serum creatinine < 2 times the upper limit of normal)Xx_NEWLINE_xXMinocycline trial only: screening results for alanine aminotransferase (ALT), if available, must be < 3 times the upper limit of normalXx_NEWLINE_xXMinocycline trial only: screening results for aspartate aminotransferase (AST) must be < 3 times the upper limit of normalXx_NEWLINE_xXAn aspartate aminotransferase (AST) less than 2 times the upper limit of normal, unless these values are due to underlying hematologic malignancyXx_NEWLINE_xXAbnormal renal function (serum creatinine level > 2X upper limit of normal [ULN]) as assessed by the central laboratory during screening.Xx_NEWLINE_xXSerum bilirubin > 1.5 x the upper limit of reference range (ULRR)Xx_NEWLINE_xXAspartate aminotransferase (AST) < 5 x upper limit of normal (ULN), unless hepatic dysfunction is a manifestation of cGVHDXx_NEWLINE_xXAspartate transaminase (AST) =< 3 x upper limit of normal (ULN)Xx_NEWLINE_xXUnexplained persistent elevation of transaminases (> 3 times upper limits of normal)Xx_NEWLINE_xXHypercalcemia (serum calcium in excess of laboratory upper limit of normal [ULN])Xx_NEWLINE_xXBlood urea nitrogen < 2 x upper limit of normal (ULN)Xx_NEWLINE_xXHematocrit >= the lower institutional limitXx_NEWLINE_xXSGOT (AST) or SGPT (ALT) < 5.0 x upper limit of normalXx_NEWLINE_xXAST and ALT <10x upper limit of normalXx_NEWLINE_xXHemoglobin greater than 90% of the lower limit of institutional normalXx_NEWLINE_xXBlood urea nitrogen (BUN) =< 1.5 x institutional upper limit of normalXx_NEWLINE_xXAST, ALT ? 2.5 x upper limit of normalXx_NEWLINE_xXHistory or presence of myopathy or raised creatine kinase (CK) >5 x upper limit of normal (ULN) on 2 occasions at screening.Xx_NEWLINE_xXAST/SGOT and ALT/SGPT ?2 x Upper Limit of Normal (ULN)Xx_NEWLINE_xXSerum bilirubin > 1.5 x the upper limit of reference range (ULRR)Xx_NEWLINE_xXMagnesium below the normal range despite supplementation, or above the CTCAE grade 1 upper limitXx_NEWLINE_xXTransaminases =< 2.5 x institutional upper limit of normal (IULN)Xx_NEWLINE_xXHypercalcemia (serum calcium in excess of laboratory upper limit normal [ULN])Xx_NEWLINE_xXLiver function: total bilirubin < 1.5 x the upper limit of normal and alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5x the upper normal limit. Patients who have been diagnosed with Gilbert's Disease are allowed to exceed the defined bilirubin value of 1.5x the upper limit of normal.Xx_NEWLINE_xXSodium, potassium, chloride, bicarbonate: all =< upper limit of institutional normalXx_NEWLINE_xXFasting triglycerides =< 1.5 x upper limit of normal (ULN)Xx_NEWLINE_xXNa within 2 x upper limit of normal (ULN)Xx_NEWLINE_xXTransaminases =< 2.5 x institutional upper limit of normal (IULN)Xx_NEWLINE_xXIndividuals with bilirubin > 2.5 x normal upper limit any time during the previous 2 monthsXx_NEWLINE_xXBilirubin = < 1.5 X upper limit of normal (ULN) except for patients (pts) with (w/) documented history of Gilbert’s disease, obtained within 14 days prior to PET scanXx_NEWLINE_xXSerum creatinine > 1.5 times upper reference rangeXx_NEWLINE_xXPre-imaging laboratory tests must be performed within 28 days prior to the [18F] FLT imaging procedure; these must be less than 4.0 times below or above the upper or lower limit range for the respective laboratory test for entry into the study (unless clinically not relevant); in those instances where a laboratory value is outside of this range, then such a patient will be ineligible for enrollment; for follow-up scanning sessions after therapy has been instituted, laboratory testing will also be required due to the use of [18F] FLT; the patients have brain tumors and will have received chemoradiation; therefore, many routine laboratory tests may not be within the typical normal range; as such, a factor of 4.0 times above or below the upper or lower value for the normal range for any laboratory test will also be used to determine the acceptable range for the 2nd and possibly 3rd imaging time points (unless clinically not relevant); the baseline laboratory testing will include liver enzymes (alanine transaminase [ALT], aspartate aminotransferase [AST]), bilirubin (total), serum electrolytes, complete blood count (CBC) with platelets, prothrombin time, partial thromboplastin time, blood urea nitrogen (BUN), and creatinine; for those patients receiving coumadin or another anticoagulant the upper limit for prothrombin time or partial thromboplastin time must not exceed 6 times the upper limit of the normal rangeXx_NEWLINE_xXSUB-STUDY I: Liver transaminases > 5 times the upper limit of normalXx_NEWLINE_xXSUB-STUDY II: Liver transaminases > 5 times the upper limit of normalXx_NEWLINE_xXSUB-STUDY III: Liver transaminases > 5 times the upper limit of normalXx_NEWLINE_xXLiver transaminases > 5 times the upper limit of normalXx_NEWLINE_xXPre-treatment laboratory tests for patients receiving [18F]FMISO must be performed within 21 days prior to the FMISO scan; these laboratory tests must be less than 4.0 times below or above the upper or lower limit range for the respective laboratory test for entry into the study (unless not clinically relevant); for those patients receiving Coumadin or another anticoagulant the upper limit for prothrombin time or partial thromboplastin time must not exceed 6 times the upper limit of the normal rangeXx_NEWLINE_xXGamma-glutamyl transpeptidase (GGT) less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXLactate dehydrogenase (LDH) less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXAmylase less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXAlbumin less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXSodium less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXPotassium less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXChloride less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXBicarbonate (HCO3) less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXCalcium less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXPhosphorus less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXCreatinine less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXUrea nitrogen less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXGlucose less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXComplete blood count (CBC) with platelets less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXProthrombin time less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXBlood urea nitrogen (BUN) less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXPre-treatment laboratory tests for patients receiving [18F]FLT must be performed within 21 days prior to study entry; these must be less than 4.0 times below or above the upper or lower limit range for the respective laboratory test for entry into the study (unless clinically not relevant); in those instances where a baseline laboratory value is outside of this range, then such a patient will be ineligible for enrollment; for the follow-up scanning sessions after therapy has been instituted, laboratory testing will also be required due to the use of FLT; the patients have brain tumors and will have received various forms of therapy; therefore, many routine laboratory tests may not be within the typical normal range; as such, a factor of 4.0 times above or below the upper or lower value for the normal range for any laboratory test will also be used to determine the acceptable range for the 2nd and possible 3rd imaging time points (unless clinically not relevant); the baseline laboratory testing will include liver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase [ALK], lactate dehydrogenase [LDH]), bilirubin (total), serum electrolytes, complete blood count (CBC) with platelets and, prothrombin time, partial thromboplastin time, blood urea nitrogen (BUN), creatinine; previous urinalysis abnormalities will not preclude the patient from being studied; for those patients receiving Coumadin or another anticoagulant the upper limit for prothrombin time or partial thromboplastin time must not exceed 6 times the upper limit of the normal rangeXx_NEWLINE_xXSerum creatinine =< 1.5 times upper reference rangeXx_NEWLINE_xXSerum ferritin < 2.0 X institutional upper limit of normalXx_NEWLINE_xXLiver function tests (LFTS) =< 1.5 x upper limit of normal (ULN)Xx_NEWLINE_xXSerum ferritin < 2.0 X institutional upper limit of normalXx_NEWLINE_xXLactate dehydrogenase (LDH) less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXSerum electrolytes less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXComplete blood count (CBC) with platelets less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXProthrombin time less than 2.5 times below or above the upper or lower limit range; for those patients receiving Coumadin or another anticoagulant the upper limit for prothrombin time must not exceed 6 times the upper limit of the normal rangeXx_NEWLINE_xXPartial thromboplastin time less than 2.5 times below or above the upper or lower limit range; for those patients receiving Coumadin or another anticoagulant the upper limit for partial thromboplastin time must not exceed 6 times the upper limit of the normal rangeXx_NEWLINE_xXBlood urea nitrogen (BUN) less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXCreatinine less than 4.0 times below or above the upper or lower limit rangeXx_NEWLINE_xXUrinalysis less than 4.0 times below or above the upper or lower limit range; urinalysis abnormalities will not preclude the patient from being enrolled and studiedXx_NEWLINE_xXHepatic enzymes 5 times greater than the upper limits of normalXx_NEWLINE_xXAspartate aminotransaminase (AST) =< 2.5 x upper limit of normal (ULN) (=< 5.0 x in case of liver [metastases] mets), within 2 weeks prior to study startXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 4.0 X upper limit of normal (ULN) or lower limit of normal (LLN)Xx_NEWLINE_xXPre-treatment laboratory tests for patients receiving fluorine F 18 fluorothymidine ([18F]FLT) must be performed within 21 days prior to baseline imaging; these laboratory tests must be less than 4.0 times below or above the upper or lower limit range for the respective laboratory test for entry into the study (unless not clinically relevant); 2.5 x for prothrombin time and partial thromboplastin time; for those patients receiving Coumadin or another anticoagulant the upper limit for prothrombin time or partial thromboplastin time must not exceed 6 times the upper limit of the normal range; the initial 4.0 x value will be critical for liver function test results which can be extremely variable, and a 4.0 x above the upper normal range is still acceptable for inclusion in this study; urinalysis abnormalities will not preclude the patient from being enrolled and studied; the baseline and subsequent laboratory testing will include liver enzymes (serum glutamic oxaloacetic transaminase [SGOT], serum glutamate pyruvate transaminase [SGPT], anaplastic lymphoma kinase [ALK]), bilirubin (total), serum electrolytes, complete blood count (CBC) with platelets prothrombin time, partial thromboplastin time, blood urea nitrogen (BUN), and creatinineXx_NEWLINE_xXFor the follow-up scanning sessions after therapy has been instituted and within 7 days prior to the second [18F]FLT study the laboratory assessments will be required due to the use of [18F]FLT; these studies should also be less than 4.0 times below or above the upper or lower limit range for the respective laboratory study (unless not clinically relevant); 2.5 x for prothrombin time and partial thromboplastin time; however at the discretion of the study principal investigator (PI) the second imaging sessions can occur if laboratory values are not within the 4 X upper limit of normal (unless not clinically relevant); for those patients receiving Coumadin or another anticoagulant the upper limit for prothrombin time or partial thromboplastin time must not exceed 6 times the upper limit of the normal range; for the assessments at subsequent imaging time points the laboratory tests as described for baseline assessment will again be obtainedXx_NEWLINE_xXAspartate aminotransaminase (AST) =< 2.5 x upper limit of normal (ULN)Xx_NEWLINE_xXAdequate bone marrow reserves (neutrophil count >1.5 x109 /l and platelet count >100 x109/l), adequate renal function (serum creatinine ? 1.5 x upper limit of normal) and hepatic function (ALAT, ASAT ? 2.5 x upper limit of normal, alkaline phosphatase ? 2.5 x upper limit of normal and total bilirubin ? 2.0 x upper limit of normal).Xx_NEWLINE_xXCardiac troponin (cTn) levels above the upper limit of normalXx_NEWLINE_xXParticipants must have serum calcium (corrected for albumin level) =< 1 x institutional upper limit of normal (ULN)Xx_NEWLINE_xXPT and PTT ? 1.5 times the upper limit of normalXx_NEWLINE_xXPatients should have adequate hepatic function with a total bilirubin within normal range and serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) < two times the upper limit of normal (ULN) for patients without liver metastasis and SGOT or SGPT < five times ULN for those with liver metastasis, and adequate renal function as defined by a serum creatinine within 1.5 times the upper limit of normal.Xx_NEWLINE_xXAST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normalXx_NEWLINE_xXbilirubin <2x upper limit of normal for ageXx_NEWLINE_xXalanine aminotransferase <3x upper limit of normal for age (<135 U/mL)Xx_NEWLINE_xXbilirubin ? 1.5 mg/dL; alanine aminotransferase (ALT), aspartate transaminase (AST) ? 2.5 times the upper limit of normal if no liver involvement or ? 5 times the upper limit of normal with liver involvement.Xx_NEWLINE_xXLVEF < 45% or below the institutional lower limit of the normal range (whichever is higher)Xx_NEWLINE_xXAdequate baseline hematological and organ function, assessed by laboratory values prior to study treatment as follows: absolute neutrophil count (ANC) > 1.0 x 109/L; hemoglobin > 7 g/dL; serum creatinine < 2 x institutional upper limit of normal (IULN); aspartate transaminase (AST) < 2.5 x IULN; alanine transaminase (ALT) < 2.5 x IULN; (if liver metastases are present, ALT and AST < 5 x IULN); total bilirubin < 1.5 x IULN.Xx_NEWLINE_xXAST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normalXx_NEWLINE_xXAST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normalXx_NEWLINE_xX